SCHEMBL26426439

SCHEMBL26426439

C#Cc1cc(OC(F)(F)F)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 5/20 0.42
PDE2A O00408 1/20 0.38
FFAR4 Q5NUL3 4/20 0.37
FFAR1 O14842 2/20 0.37
TRPA1 O75762 1/20 0.37
KIF11 P52732 1/20 0.37
CES1 P23141 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
GMNN O75496 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29870653 1.00 GPR3 (0.42) GPR3PDE2AFFAR4FFAR1TRPA1
SCHEMBL8533827 0.85 GPR3 (0.42) GPR3PDE2AFFAR4FFAR1TRPA1
SCHEMBL1263373 0.81 GPR3 (0.42) GPR3PDE2ATRPA1TP53CYP3A4
SCHEMBL16955159 0.81 GPR3 (0.42) GPR3PDE2AFFAR4FFAR1TRPA1
SCHEMBL25468202 0.80 GPR3 (0.41) GPR3FFAR4KIF11CES1NPC1
SCHEMBL28060123 0.77 EGFR (0.41) CYP1A2
SCHEMBL29172848 0.76 GPR3 (0.41) GPR3FFAR4FFAR1KIF11CES1
SCHEMBL26426444 0.75 GPR3 (0.38) GPR3PDE2AFFAR4FFAR1TRPA1
SCHEMBL31135361 0.74 GPR3 (0.40) GPR3PDE2AFFAR4FFAR1TRPA1
SCHEMBL7645001 0.73 TACR1 (0.39) GPR3KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2026-03-17 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
EP-4110777-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) 2023-01-04 EP disclosed
CN-115175909-A Pyrrolopyridine and imidazopyridine antiviral compounds 鲁汶天主教大学 2022-10-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS SARS1, TPI1, TPMT GPR3 4335/4885PDE2A 1679/4885FFAR4 4686/4885
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds SARS1, TPMT, ZC3HAV1 GPR3 3374/4885PDE2A 3311/4885FFAR4 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.